The J-Valve TF System is intended to address the unmet needs of patients suffering from aortic valve regurgitation in the US. Credit: Natali _ Mis/shutterstock.com.

Genesis MedTech has announced the completion of enrollment for its early feasibility study (EFS) in the US, evaluating the J-Valve TF System for patients with severe aortic regurgitation (AR).

The J-Valve TF System is designed for a minimally invasive transfemoral approach, eliminating the need for an open-heart procedure.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It is intended to address the unmet needs of patients suffering from aortic valve regurgitation in the US.

Approved by the US Food and Drug Administration (FDA), the EFS trial enrolled patients at five US centres, focusing on symptomatic individuals with severe aortic regurgitation.

The last participant was enrolled at MedStar Washington Hospital Center by Drs Ron Waksman and Lowell Satler.

Co-principal investigators of the study were Dr Dean Kereiakes from the Christ Hospital Heart and Vascular Institute and Dr Michael Reardon from Houston Methodist Hospital.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Patients who met the inclusion criteria were treated with the J-Valve TF system. The outcomes from this clinical experience are expected to be presented later in the year.

Developed by Genesis’ subsidiary JC Medical, the J-Valve TF System has received breakthrough device designation for treating severe native aortic regurgitation and AR-dominant mixed aortic valve disease.

Currently, the J-Valve TF System is an investigational device in the US and Canada.

Reardon said: “TAVR has proven results for patients with Aortic Stenosis. An unmet need remains for patients with Aortic Regurgitation.

“The J-Valve being a dedicated TAVR design has shown promise in treating patients with aortic regurgitation. We are pleased with our findings to date from our EFS and look forward to the successful initiation of the pivotal trial.”

In October 2023, Genesis MedTech started enrolment for an early feasibility study using its J-TF system in North America.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact